BR0112101A - Interleucina 2 estabilizada - Google Patents

Interleucina 2 estabilizada

Info

Publication number
BR0112101A
BR0112101A BR0112101-4A BR0112101A BR0112101A BR 0112101 A BR0112101 A BR 0112101A BR 0112101 A BR0112101 A BR 0112101A BR 0112101 A BR0112101 A BR 0112101A
Authority
BR
Brazil
Prior art keywords
stabilized
interleukin
variant
preferred formulation
interleucin
Prior art date
Application number
BR0112101-4A
Other languages
English (en)
Other versions
BR0112101B1 (pt
Inventor
Wei Wang
Rajiv Nayar
Michael A Shearer
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24424265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0112101(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR0112101A publication Critical patent/BR0112101A/pt
Publication of BR0112101B1 publication Critical patent/BR0112101B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Train Traffic Observation, Control, And Security (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Sub-Exchange Stations And Push- Button Telephones (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"INTERLEUCINA 2 ESTABILIZADA". A preparação farmacêutica estável compreendendo interleucina2 Humana ou uma variante desta e uma quantidade estabilizante de histidina. A formulação preferida inclui glicina e sacarose e uma variante de IL-2 tendo uma mutação única, N88R. A formulação preferida é na forma liofilizada, que sob reconstituição com um diluente aquoso, resulta em uma solução tendo um pH variando de cerca de 5,0 a 6,5.
BRPI0112101A 2000-06-28 2001-06-27 Interleucin 2 stabilized BR0112101B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/605,577 US6689353B1 (en) 2000-06-28 2000-06-28 Stabilized interleukin 2
PCT/US2001/020675 WO2002000243A2 (en) 2000-06-28 2001-06-27 Stabilized interleukin 2

Publications (2)

Publication Number Publication Date
BR0112101A true BR0112101A (pt) 2004-07-06
BR0112101B1 BR0112101B1 (pt) 2017-11-14

Family

ID=24424265

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0112101A BR0112101B1 (pt) 2000-06-28 2001-06-27 Interleucin 2 stabilized

Country Status (24)

Country Link
US (1) US6689353B1 (pt)
EP (1) EP1370280B1 (pt)
JP (3) JP5522878B2 (pt)
KR (1) KR100799402B1 (pt)
CN (1) CN1523997B (pt)
AR (1) AR029139A1 (pt)
AU (1) AU2001273063A1 (pt)
BR (1) BR0112101B1 (pt)
CA (1) CA2413334C (pt)
CO (1) CO5290308A1 (pt)
CU (1) CU23536A3 (pt)
DE (1) DE60142412D1 (pt)
DO (1) DOP2001000197A (pt)
EC (1) ECSP014106A (pt)
ES (1) ES2344729T3 (pt)
HN (1) HN2001000139A (pt)
IL (2) IL153587A0 (pt)
MX (1) MXPA03000046A (pt)
MY (1) MY128629A (pt)
PE (1) PE20020127A1 (pt)
SV (1) SV2002000512A (pt)
TW (1) TWI235063B (pt)
UY (1) UY26805A1 (pt)
WO (1) WO2002000243A2 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8531276B2 (en) * 2000-03-15 2013-09-10 Logitech Europe S.A. State-based remote control system
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP5057648B2 (ja) * 2002-09-26 2012-10-24 塩野義製薬株式会社 安定化されたタンパク組成物
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
EP3167961A1 (en) * 2004-04-08 2017-05-17 Biomatrica, Inc. Integration of sample storage and sample management for life science
CN101171033A (zh) * 2005-03-04 2008-04-30 戴纳瓦克斯技术公司 包含具免疫刺激序列iss之寡核苷酸的疫苗：其中iss与抗原缀合并通过缓冲条件和其他赋形剂稳定
WO2007106746A2 (en) * 2006-03-10 2007-09-20 Dyax Corp. Formulations for ecallantide
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
MX2009012964A (es) 2007-06-01 2010-01-14 Acologix Inc Formulacion de peptido estable a alta temperatura.
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
CA2761675A1 (en) * 2009-05-11 2010-11-18 Biomatrica, Inc. Compositions and methods for biological sample storage
PL2498801T3 (pl) 2009-11-13 2018-08-31 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
EP2598660B1 (en) 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
CA2806734A1 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
KR102472497B1 (ko) 2010-11-12 2022-11-29 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
SG190418A1 (en) * 2010-12-02 2013-07-31 Oncolytics Biotech Inc Liquid viral formulations
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
CN103063829B (zh) * 2012-12-21 2015-01-14 杭州茂天赛科技有限公司 一种冻存液
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3154338B1 (en) 2014-06-10 2020-01-29 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
HUE051414T2 (hu) 2014-08-11 2021-03-01 Delinia Inc Módosított IL-2 változatok, amelyek szelektíven aktiválnak regulátor T sejteket, autoimmun betegségek kezelésére
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN108700498B (zh) 2015-12-08 2021-07-13 生物马特里卡公司 降低红细胞沉降速率
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
SG11201909949XA (en) 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
IL277572B2 (en) 2018-03-28 2024-05-01 Ascendis Pharma Oncology Div A/S IL-2 conjugates
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
KR20220114595A (ko) 2019-12-17 2022-08-17 암젠 인크 치료에서의 사용을 위한 이중 인터류킨-2/tnf 수용체 효현제
US20210187027A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
AU2021206449A1 (en) 2020-01-10 2022-07-21 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
KR102653906B1 (ko) 2020-01-14 2024-04-03 신테카인, 인크. 편향된 il2 뮤테인 방법 및 조성물
EP4107187A1 (en) 2020-02-21 2022-12-28 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
EP4161956A1 (en) 2020-06-03 2023-04-12 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20230398183A1 (en) * 2020-11-13 2023-12-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60215631A (ja) * 1984-04-09 1985-10-29 Takeda Chem Ind Ltd インタ−ロイキン−２組成物
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
JPH0645551B2 (ja) * 1986-01-07 1994-06-15 塩野義製薬株式会社 インタ−ロイキン−２組成物
JPH0229016A (ja) * 1989-06-09 1990-01-31 Alpine Electron Inc イコライザ装置
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
JP2001511437A (ja) * 1997-07-31 2001-08-14 ロディア・シミ 官能化されたポリオルガノシロキサンを含む化粧品組成物
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2

Also Published As

Publication number Publication date
IL153587A0 (en) 2003-07-06
AR029139A1 (es) 2003-06-04
MY128629A (en) 2007-02-28
SV2002000512A (es) 2002-07-03
HN2001000139A (es) 2003-12-11
WO2002000243A3 (en) 2003-10-02
AU2001273063A1 (en) 2002-01-08
CN1523997B (zh) 2010-09-01
KR20030016312A (ko) 2003-02-26
JP2004532791A (ja) 2004-10-28
KR100799402B1 (ko) 2008-01-30
MXPA03000046A (es) 2003-06-19
US6689353B1 (en) 2004-02-10
TWI235063B (en) 2005-07-01
CU23536A3 (es) 2010-06-17
DOP2001000197A (es) 2003-01-15
ES2344729T3 (es) 2010-09-06
EP1370280A2 (en) 2003-12-17
IL153587A (en) 2007-12-03
WO2002000243A2 (en) 2002-01-03
JP2012211166A (ja) 2012-11-01
BR0112101B1 (pt) 2017-11-14
EP1370280B1 (en) 2010-06-16
JP5522878B2 (ja) 2014-06-18
ECSP014106A (es) 2002-02-25
CO5290308A1 (es) 2003-06-27
CN1523997A (zh) 2004-08-25
PE20020127A1 (es) 2002-04-27
JP2015007114A (ja) 2015-01-15
CA2413334C (en) 2011-03-08
DE60142412D1 (de) 2010-07-29
UY26805A1 (es) 2002-01-31
CA2413334A1 (en) 2002-01-03
JP5989728B2 (ja) 2016-09-07

Similar Documents

Publication Publication Date Title
BR0112101A (pt) Interleucina 2 estabilizada
ATE230277T1 (de) Stabilisierte antikörperformulierung
EP0340592A3 (de) Haarbehandlungsmittel mit natürlichen Inhaltsstoffen
BRPI0208210B8 (pt) preparação de insulina pobre em zinco e isenta de zinco com estabilidade aperfeiçoada
BR9907647A (pt) Composições contendo composto orgânicos
BRPI0412241A (pt) formulação para medicamentos de proteìna sem adição de albumina de soro humano (hsa)
BRPI0311877B8 (pt) formulação farmacêutica ácida de insulina com estabilidade aperfeiçoada
DK0760677T3 (da) Farmaceutisk præparat omfattende glucagon
BR0116831A (pt) Composição oral e seu uso
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
SI2236154T1 (en) THE FORM OF IMUNOGLOBULIN AND THE METHOD OF ITS PREPARATION
BR9714434A (pt) Formulações de interferon liquidas estáveis
BR9913343A (pt) Formulações de caseìna para a distribuição de constituintes bioativos
BR0012082A (pt) Formulação farmacêutica para administração compreendendo morfina e seu uso
DE60108154D1 (de) Pharmazeutische Zubereitungen enthaltend Clavulansäure
DK157689D0 (da) Farmaceutiske piroxicammidler i vandige oploesninger samt fremgangsmaade til fremstilling heraf
BR0115518A (pt) Kit de repinotan
BR9807112A (pt) Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato
BR9913135A (pt) Formulação oral
BR9909357A (pt) Solução ou suspensão de mirtazapina em mistura com água, formulação farmacêutica compreendendo mirtazapina, e, uso de mirtazapina
BR0209206A (pt) Clatrato de hidrato de azitromicina com 1,2-propileno glicol, processo para a sua preparação e composição farmacêutica compreendendo o mesmo
BR9610388A (pt) Composto de pirimidina ou um seu sal de adição de ácido processo para a preparação de uma pirimidina e formulação farmacêutica
FI943103A (fi) Puolikiinteä farmaseuttinen aine ja menetelmä sen valmistamiseksi
DE69928279D1 (de) Lungensurfactant zubereitungen enthaltendes behandlungset
YU39396A (sh) Upotreba izolovanog prirodnog proteina gojaznosti za pripremu leka i njegova farmaceutska formulacija

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: AICURIS GMBH AND CO. KG (DE)

Free format text: TRANSFERIDO DE: BAYER CORPORATION

B25G Requested change of headquarter approved

Owner name: AICURIS GMBH AND CO. KG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020090023412/RJ DE 11/03/2009.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDAS DA PETICAO NO 020090023404/RJ DE 11/03/2009, OS PEDIDOS DE TRANSFERENCIA DE TITULAR E DE ALTERACAO DE SEDE, POR AUSENCIA DE FUNDAMENTACAO LEGAL, UMA VEZ QUE AS SOLICITACOES JA FORAM PUBLICADAS NAS RPI'S 2015 DE 18/08/2009 E 2018 DE 08/09/2009.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2626 DE 04-05-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.